Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 2/20 | 0.44 |
| ▸ | ADH1C | P00326 | 2/20 | 0.44 |
| ▸ | ADH1A | P07327 | 2/20 | 0.44 |
| ▸ | ADH4 | P08319 | 2/20 | 0.44 |
| ▸ | ADH7 | P40394 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.42 |
| ▸ | GAPDH | P04406 | 1/20 | 0.42 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884535 | 1.00 | ADH1B (0.44) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL11251404 | 0.98 | TRPA1 (0.44) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL5941933 | 0.91 | — | — | |
| SCHEMBL11898466 | 0.91 | FAAH (0.52) | MAPTTSHRFFAR1LMNA | |
| SCHEMBL28600523 | 0.86 | ADH1B (0.47) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL11858120 | 0.84 | ADH1B (0.45) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL13922054 | 0.81 | — | — | |
| SCHEMBL4048543 | 0.81 | — | — | |
| SCHEMBL31347979 | 0.81 | ADH1B (0.42) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL11219107 | 0.81 | ADH1B (0.42) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8816095-B2 | Na channels, disease, and related assays and compositions | GEORGETOWN UNIVERSITY (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110230442-A1 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | GEORGETOWN UNIVERSITY (US) | 2011-09-22 | — | — | US | disclosed |
| EP-2343974-A2 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | Georgetown University (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010027641-A2 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | GEORGETOWN UNIVERSITY (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010019963-A2 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | GEORGETOWN UNIVERSITY (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230442-A1 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | CACNA1C, CACNA1B, CACNA1A | ADH1B 4568/4885ADH1C 3639/4885ADH1A 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.